Log in to search using one of your social media accounts:

 

Roche and Chiasma announce collaboration to develop and commercialize Chiasma's Octreolin for acromegaly and neuroendocrine tumors

Roche and Chiasma (pronounced key-azma) Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma’s proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors. Octreolin is an investigational oral form of the peptide octreotide, a somatostatin analog that is commercially available only by injection. Octreolin is currently in a pivotal phase 3 clinical trial for acromegaly. Under the terms of the agreement, Roche received a worldwide exclusive license to Octreolin, and will assume responsibility for the commercialization of Octreolin. Genentech will market the product in the United States after US FDA approval.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: GuimarãesSá AM, Ferreira PAM, Souza MT, Nascimento GC, da Silva Pereira Damianse S, de Carvalho Rocha VC, Dos Santos Faria M, de Souza Paiva Ferreira A Abstract Objective: To identify the factors associated with quality of life in patients with acromegaly with follow-up at the referral service in neuroendocrinology of the state of Maranhão, northeast Brazil. Methods: The Acromegaly Quality of Life Questionnaire (Acro-QoL) was used. Factors independently associated with quality of life were identified using multivariate linear regression, with p values 
Source: International Journal of Endocrinology - Category: Endocrinology Tags: Int J Endocrinol Source Type: research
AbstractA heterogeneous group of epithelial cystic tumors developed at the infundibulum and the third ventricle disconcerted pathologists at the dawn of the twentieth century. Very little was known at that time about the physiological role played by the pituitary gland, and there was almost complete ignorance regarding the function of the hypothalamus. Acromegaly, or enlargement of acral body parts, described in 1886 by Pierre Marie, was the only disease linked to primary hypertrophies of the pituitary gland, known as “pituitary strumas”. A growing number of young patients manifesting an unexplained combination...
Source: Pituitary - Category: Endocrinology Source Type: research
Clinical Endocrinology, EarlyView.
Source: Clinical Endocrinology - Category: Endocrinology Authors: Source Type: research
KIP SULLIVAN Lawton Burns and Mark Pauly, economists at the Wharton School, just published an article that should be required reading for all policy makers and health services researchers. The article,  entitled “Transformation of the health care industry: Curb your enthusiasm,” appears in the latest edition of the Milbank Quarterly. Burns and Pauly undertook an enormous task and executed it well. They first sought to explain the assumptions underlying Managed Care (MC) 2.0 – the proposals promoted by the managed care movement in the wake of the HMO backlash of the late 1990s. Then they evaluat...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Uncategorized Source Type: blogs
Publication date: Available online 17 March 2018 Source:Best Practice & Research Clinical Endocrinology & Metabolism Author(s): Giampaolo Trivellin, Laura C. Hernández-Ramírez, Jeremy Swan, Constantine A. Stratakis X-linked acrogigantism (X-LAG) is a recently described form of familial or sporadic pituitary gigantism characterized by very early onset GH and IGF-1 excess, accelerated growth velocity, gigantism and/or acromegaloid features. Germline or somatic microduplications of the Xq26.3 chromosomal region, invariably involving the GPR101 gene, constitute the genetic defect leading to X-LAG. G...
Source: Best Practice and Research Clinical Endocrinology and Metabolism - Category: Endocrinology Source Type: research
ConclusionThe technique presented herein effectively improved the quality of life of patients with acromegaly with different levels of disease activity, type, and treatment time.
Source: Pituitary - Category: Endocrinology Source Type: research
In this study, we aimed to evaluate the presence of glucose metabolism abnormalities and their impact on IGF-1 levels in patients with acromegaly. Ninety-three patients with acromegaly (n=93; 52 males/41 females) were included in this study. Patients were separated into three groups such as; normal glucose tolerance (n=23, 25%), prediabetes (n=38, 41%), and diabetes mellitus (n=32, 34%). Insulin resistance was calculated with homeostasis model assessment (HOMA). HOMA-IR> 2.5 or ≤2.5 were defined as insulin resistant or noninsulin resistant groups, respectively. Groups were compared in terms of factors that may...
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Tags: Endocrine Care Source Type: research
ConclusionsOur data demonstrate a low prevalence of acromegaly in patients with OSAS. Until data from population-based studies is available we suggest restricting screening for acromegaly in OSAS to those patients who have additional clinical features of acromegaly.
Source: Endocrine - Category: Endocrinology Source Type: research
AbstractBackgroundTranssphenoidal surgery (TSS) is the cornerstone of acromegaly treatment, however there are no robust predictors of surgical outcome and remission can only be defined three months after surgery.PurposeTo analyze if biochemical, demographical, radiological, and immunohistochemical characteristics are predictors of surgical remission and investigate if immediate postoperative GH and IGF-I levels can help defining remission earlier.MethodsConsecutive acromegaly patients submitted to TSS between 2013-2016 were evaluated. Remission criteria was defined as normal IGF-I and GH
Source: Endocrine - Category: Endocrinology Source Type: research
Clinical Endocrinology, EarlyView.
Source: Clinical Endocrinology - Category: Endocrinology Authors: Source Type: research
More News: Acromegaly | Clinical Trials | Neurology | Pharmaceuticals